
10019993.050602



1. A compound of formula I

$$\begin{array}{c|c}
O \\
N \longrightarrow (X)_n \longrightarrow \\
R^2 \\
R^3
\end{array}$$

wherein:

5

10

15

 R^{1} is hydrogen, C_1 - C_4 alkyl, or C_2 - C_4 alkenyl;

R² and R³ independently are hydrogen, C₁-C₄ alkyl, phenyl or benzyl, or taken together with the nitrogen to which they are attached complete a ring having from 4 to 7 ring atoms, one optionally being oxygen;

X is $(CH_2)_n$, CHMe- $(CH_2)_{n-1}$ or $(CH_2)_{n-1}$ -CHMe,

n is 1, 2 or 3;

R⁴ is an aromatic or heteroaromatic group selected from

wherein R⁵ is hydrogen, halogen, C₁-C₄ alkyl, nitro, N₃ or CF₃ and R⁶ is hydrogen, C₁₋₄

alkyl, -(C=O)Me, -(C=O)NH₂,
$$O \cap Ph$$
 or $O \cap Me$ Me

and the pharmaceutically acceptable salts thereof.



- 2. A compound according to claim 1 wherein R^1 is C_1 - C_4 alkyl.
- 3. A compound according to Claim 2 wherein R^2 and R^3 independently are C_1 - C_4 alkyl.


24


- 4. A compound according to Claim 3 wherein n is 2 or 3. 5
 - 5. A compound according to Claim 4 wherein R⁴ is selected from

$$\begin{array}{c|c} & CI & CF_3 & Br \\ \hline \\ O_2N & \\ \end{array}$$
 and
$$\begin{array}{c|c} CF_3 & CH_3 \\ \end{array}$$

6. A compound according to Claim 4 wherein R⁴ is selected from

7. A compound according to Claim 4 wherein R⁴ is selected from






8. A compound according to Claim 4 wherein R⁴ is selected from

$$CF_3$$
 and CF_3

9. A compound according to Claim 4 wherein R⁴ is selected from



5

10

10. A compound according to Claim 4 wherein R⁴ is selected from


,
$$\bigcap_{N \to CI}^{NO_2}$$
 and $\bigcap_{I \to Bu}^{N}$

11. A compound according to Claim 4 wherein R⁴ is selected from

$$CF_3$$
 and CF_3

12. A compound according to Claim 4 wherein R⁴ is selected from

$$\bigcap_{NO_2} \bigcap_{O} \bigcap$$



13. A compound according to Claim 4 wherein R⁴ is selected from

$$\bigcap_{C} \bigcap_{N} \bigcap_{N} \bigcap_{CF_3} \bigcap_{NO_2} \bigcap_{NO_2} \bigcap_{NO_2} \bigcap_{NO_2} \bigcap_{NO_2} \bigcap_{CH_3} \bigcap$$

5 14. A compound according to Claim 4 wherein R⁴ is selected from

15. A compound according to any one of Claims 5 to 14 which is selected from

N-Propionyl, N-(2-Diethylaminoethyl)-1-amino-4-chloronaphthalene

N-Propionyl, N(2-Diethylaminoethyl)-4-amino-9-fluorenone

N-Propionyl, N-(2-Diethylaminoethyl)- 1-amino-4-bromonaphthalene

N-Propionyl, N-(N-Morpholino)-1-amino-4-chloronaphthalene

N-Propionyl, N-(2- (3-diethylamino-propyl))-1-amino-4-chloronaphthalene

N-Propionyl, N-(2-Diethylaminoethyl)-1-amino-4-azidonaphthalene

N-Propionyl, N-(2-Diethylaminoethyl)-3-chlorobenzyl-amine

N-Propionyl, N-(2-Diethylaminoethyl)-3-bromobenzyl-amine

N-Propionyl, N-(2-Piperidx)ethyl)-1-amino-4-chloronaphthalene

N-Propionyl, N-(2-(3-dimethylamino-propyl))-1-amino-4-chloronaphthalene

N-Propionyl, N-(2-Dimethylaminoethyl)-1-amino-4-chloronaphthalene

N-Propionyl, N-(2-(N-benzyl)-ammoethyl)-1-ammonaphthalene


N-(2-Diethylamino-ethyl)-N-(7-methyl-quinolin-4-yl) propionamide

N-Acryloyl, N-(2-diethylaminoethyl)-1-amino-4-chloronaphthalene, and

N-Propionyl, N-(2-Diethylaminoethyl)-(\frac{1}{2}-amino-4-nitronaphthalene).

- 16. N-Propionyl, N-(2-Diethylaminoethyl)-1-amino-4-chloronaphthalene.
- 17. N-Propionyl, N-(2-Diethylaminoethyl)-4-amino-9-fluorenone.

10



- 18. N-Propionyl, N-(2-Diethylaminoethyl)- 1-amino-4-bromonaphthalene.
- 19. N-Propionyl, N-(N-Morpholino)-1-amino-4-chloronaphthalene.

5

25

- 20. N-Propionyl, N-(2- (3-diethylamino-propyl))-1-amino-4-chloronaphthalene.
- 21. N-Propionyl, N-(2-Diethylaminoethyl)-1-amino-4-azidonaphthalene.
- 22. N-Acryloyl, N-(2-diethylaminoethyl)-1-amino-4-chloronaphthalene.
 - 23. N-Propionyl, N-(2-Diethylaminoethyl)-(1-amino-4-nitronaphthalene).
- 24. A compound according to any one of Claims 1 to 23 which is a pharmaceutically acceptable salt.
 - 25. A pharmaceutical formulation comprising a compound of any one of Claims 1 to 24 together with a pharmaceutically acceptable diluent, carrier or excipient therefor.
- 26. A method for treating a CNS disorder in a mammal in need of treatment comprising administering a CNS effective amount of a compound of any one of Claims 1 to 24.
 - 27. A method according to claim 26 wherein the CNS disorder is selected from pain, depression, anxiety, or schizophrenia.
 - 28. A method according to Claim 26 wherein the CNS disorder is selected from Huntington's disease, Alzheimer's disease or amyotrophic lateral sclerosis.